Presentation and management of docetaxel-related adverse effects in patients with breast cancer - Wikidata - wikimedia - TriplyDB

Presentation and management of docetaxel-related adverse effects in patients with breast cancer

Presentation and management of docetaxel-related adverse effects in patients with breast cancer

http://www.wikidata.org/entity/Q33698286

about

Trastuzumab-Associated Flagellate Erythema: Report in a Woman with Metastatic Breast Cancer and Review of Antineoplastic Therapy-Induced Flagellate Dermatoses.Serious neutropenia following neoadjuvant chemotherapy for locally advanced breast cancer: A case report Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.New Insights toward Colorectal Cancer Chemotherapy Using Natural Bioactive Compounds.A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.Difference in Neutropenia due to Administration Schedule of TAS-102.Genetic background influences susceptibility to chemotherapy-induced hematotoxicity.Translational opportunities for broad-spectrum natural phytochemicals and targeted agent combinations in breast cancer.Docetaxel-induced cardiac-respiratory arrest in a patient with chronic atrial fibrillation.Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial.

P2860

Q36359992-98081793-20A0-436B-AAAD-646D0FF5D6D5 Q36524744-89260DC4-8196-407A-99B4-4C18C47B40F5 Q37662576-A1299CE3-CCA1-46E8-AB5E-DC429DCF1ECF Q37697414-BD6416F6-1F7A-4647-9DCE-A301D9D416C1 Q38701979-DC4D7F23-A699-4E5C-8A84-7D3A7FFD040F Q40173668-782F394B-C385-4906-B8CF-5F6F90F4F513 Q47094464-585378AA-FCD6-4143-8C5B-99C1D9840B8E Q47567895-660A3DA4-E73D-454F-B9D3-C9AD6E428E4B Q47856786-CB676227-3390-49D2-B302-B1D12B029B3C Q48212362-1172A5AD-BB35-4C7F-B6A5-A1959A03C063

P2860

Presentation and management of docetaxel-related adverse effects in patients with breast cancer

http://www.wikidata.org/entity/Q33698286

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Presentation and management of ...... in patients with breast cancer

@ast

Presentation and management of ...... in patients with breast cancer

@en

type

label

Presentation and management of ...... in patients with breast cancer

@ast

Presentation and management of ...... in patients with breast cancer

@en

prefLabel

Presentation and management of ...... in patients with breast cancer

@ast

Presentation and management of ...... in patients with breast cancer

@en

P1433

Q33698286-D48EB94F-C1E0-4375-93A9-B1DEAF7A3B4F

P1476

Q33698286-08FFB628-E504-49BE-8D69-3EE10D51D7D5

P2093

Q33698286-A2EB1720-590E-42BB-9DDE-AB4054D2A3AD

P2860

Q33698286-00D1F03F-001A-4450-92D1-3FE10E2155F1

Q33698286-04BF8EA3-B004-42C1-9C78-3CC8040D8E01

Q33698286-08055CA9-40C5-469B-8E5E-8217F808C6ED

Q33698286-088691CC-4670-490A-83B7-8B284FC9249F

Q33698286-0CE6DB37-21EC-4879-A6CB-217B46E4F0E3

Q33698286-1499B310-E59C-4165-BE1F-142ED4EB3A70

Q33698286-14AE8394-EE7F-4739-AA16-015CE1854253

Q33698286-1501487E-8F00-4458-BE0B-DDCCC64C2E63

Q33698286-1680828B-FD97-489F-9805-3C490BA960D9

Q33698286-182C104F-BAE5-413C-840A-69FA61D3CB95

P304

Q33698286-895A423B-DFE1-4234-BD2D-FDEE42C76030

P31

Q33698286-6A562E5A-AF60-48B8-82C2-9F58383F11E9

P356

Q33698286-C81D4546-9377-4956-B199-9A8B1523E6A3

P407

Q33698286-090EB112-B1E6-4586-97B9-B721A5E15AF5

P478

Q33698286-F06F7C77-D095-4224-9C56-2C24DD50805A

P50

Q33698286-E787AC15-1B9E-4BDA-997C-A41838C648C4

P577

Q33698286-B5984FED-D042-4566-9862-A7A995794116

P698

Q33698286-D3915520-8B2E-4BAF-9152-51A6AC47C4F5

P932

Q33698286-525B8032-F3B0-405C-AD55-F3F6AA17E96C

P356

P1433

Cancer Management and Research

P1476

Presentation and management of ...... in patients with breast cancer

@en

P2093

Maria Y Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)

Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.

P304

253-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S40601

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24904223

http://www.w3.org/2001/XMLSchema#string

P932

4041377

http://www.w3.org/2001/XMLSchema#string